Biomarkers of Replication and Injury in HBV/HIV
Biomarkers of Replication and Injury in HBV/HIV
批准号:
10326569
负责人:
KENNETH E SHERMAN
金额:
$23.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-12 至 2023-06-30
关键词:
AIDS clinical trial groupAfrica South of the SaharaAntigensBiological AssayBiological MarkersBloodBlood TestsCD4 Lymphocyte CountCategoriesChronicCirrhosisClinicalCross-Sectional StudiesDataDetectionDevelopmentDiagnosticDiseaseEnrollmentEuropeEvolutionFrequenciesFutureGene SilencingGenetic TranscriptionGhanaGoalsHIVHIV InfectionsHepatitis BHepatitis B Surface AntigensHepatitis B TherapyHepatitis B VirusHepatitis C TherapyIndividualInjuryInterventionLaboratoriesLeadLiverLiver diseasesMonitorMorbidity - disease rateNational Institute of Allergy and Infectious DiseaseNatural HistoryNucleosidesPersonsPrognosisRandomizedResearchRiskRoleSamplingSerologySerumStagingStrategic PlanningSurface AntigensTenofovirTestingTissuesTranscriptTreatment outcomeUnited States National Institutes of HealthUniversitiesValidationViralViral Load resultVirus DiseasesVirus Replicationacute infectionadefovirbasebiomarker identificationchronic infectionclinical careco-infectioncohortexosomeglobal healthinnovationinterestliver injurymortalitynovelnovel markernucleoside analogpgRNArepositoryresponseresponse biomarkertreatment responsetrial comparingtwo-arm trialviral DNAvirus core
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Hepatitis B virus (HBV) is a serious global health concern. In those with HIV it is associated with
increased risk of chronicity after acute infection, and increased rates of liver-associated
mortality. The field of HBV treatment is undergoing evolution, changing focus from HBV DNA
suppression to functional and complete HBV cure. Biomarkers that provide clear guidance
regarding prediction, treatment outcome and accurate information regarding liver injury are
limited. Though research use of newer HBV biomarkers including pgRNA, quantitative surface
antigen and HBV core-related antigen has accelerated in the last year, very limited data exists
with regard to their use and utility among persons living with HIV (PLWH). In this Exploratory
R21 application we propose to evaluate the potential role of several biomarkers that have not
been previously characterized in those with HBV/HIV coinfection. HBV pgRNA represents a
transcript of the cccDNA minichromosome that is central to development and perpetuation of
HBV chronicity. Using 3 complementary cohorts of PLWH, we will evaluate the association of
these biomarkers with CD4 count, HIV viral load and other demographic and serologic HBV
markers stratified by categorical natural history replicative stages of HBV disease. In one AIDS
Clinical Trials Group (ACTG) cohort, we will examine longitudinal changes in these biomarkers
associated with initiation of nucleoside therapy. Our laboratory has recently implemented use of
a new blood-based cccDNA assay which will be utilized in conjunction with the pgRNA assays
to determine the frequency and proportion of gene silencing. Using novel liver-derived exosome
markers of liver injury we will explore whether gene silencing is associated with lower levels of
liver injury than are identified with more traditional markers of response such as serum ALT.
This characterization will provide key information that may inform future cure strategies for HBV,
in PLWH which are being studied within the ACTG and elsewhere.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarkers of Replication and Injury in HBV/HIV
-
批准号:10449351
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2021
-
负责人:KENNETH E SHERMAN
-
依托单位:
Hepatitis E in HIV-Infected Patients
-
批准号:9335720
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2015
-
负责人:KENNETH E SHERMAN
-
依托单位:
Hepatitis E in HIV-Infected Patients
-
批准号:9049750
-
项目类别:
-
资助金额:$27.5万
-
财政年份:2015
-
负责人:KENNETH E SHERMAN
-
依托单位:
Viral kinetic models of HCV clearance in hemophiliacs treated with telaprevir
-
批准号:8472526
-
项目类别:
-
资助金额:$34.06万
-
财政年份:2012
-
负责人:KENNETH E SHERMAN
-
依托单位:
Viral kinetic models of HCV clearance in hemophiliacs treated with telaprevir
-
批准号:8302090
-
项目类别:
-
资助金额:$37.22万
-
财政年份:2012
-
负责人:KENNETH E SHERMAN
-
依托单位:
Mentorship in Liver Disease
-
批准号:8011153
-
项目类别:
-
资助金额:$4.7万
-
财政年份:2010
-
负责人:KENNETH E SHERMAN
-
依托单位:
Antiretroviral Therapy and the Hepatitis C Virus
-
批准号:7062999
-
项目类别:
-
资助金额:$71.01万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Liver Disease and HIV
-
批准号:7494760
-
项目类别:
-
资助金额:$3.1万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Liver Disease and HIV
-
批准号:8990913
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
HIV Antiretroviral Therapy and Hepatic Injury
-
批准号:9139029
-
项目类别:
-
资助金额:$56.27万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Liver Disease and HIV
-
批准号:7169429
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Liver Disease and HIV
-
批准号:8449670
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Liver Disease and HIV
-
批准号:8641652
-
项目类别:
-
资助金额:$3.2万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Antiretroviral Therapy and the Hepatitis C Virus
-
批准号:7219510
-
项目类别:
-
资助金额:$69.67万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
HIV and Liver Disease Conference
-
批准号:10391428
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Antiretroviral Therapy and the Hepatitis C Virus
-
批准号:7797657
-
项目类别:
-
资助金额:$55.23万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Antiretroviral Therapy and the Hepatitis C Virus
-
批准号:7390359
-
项目类别:
-
资助金额:$68.66万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Liver Disease and HIV
-
批准号:7848330
-
项目类别:
-
资助金额:$4.19万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
Antiretroviral Therapy and the Hepatitis C Virus
-
批准号:7609061
-
项目类别:
-
资助金额:$77.4万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
HIV and Liver Disease Conference
-
批准号:10596534
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2006
-
负责人:KENNETH E SHERMAN
-
依托单位:
海外基金